Your browser is no longer supported. Please, upgrade your browser.
Sage Therapeutics, Inc.
Index- P/E3.84 EPS (ttm)11.84 Insider Own1.10% Shs Outstand58.58M Perf Week-2.11%
Market Cap2.72B Forward P/E- EPS next Y-6.09 Insider Trans5.49% Shs Float51.54M Perf Month4.20%
Income666.20M PEG0.09 EPS next Q-1.88 Inst Own86.80% Short Float3.67% Perf Quarter-22.15%
Sales1.11B P/S2.44 EPS this Y185.50% Inst Trans-5.25% Short Ratio2.85 Perf Half Y-38.41%
Book/sh32.94 P/B1.38 EPS next Y17.30% ROA38.10% Target Price- Perf Year-22.89%
Cash/sh31.95 P/C1.42 EPS next 5Y41.10% ROE40.00% 52W Range39.77 - 98.39 Perf YTD-47.50%
Dividend- P/FCF- EPS past 5Y39.90% ROI28.80% 52W High-53.83% Beta1.88
Dividend %- Quick Ratio27.70 Sales past 5Y- Gross Margin99.90% 52W Low14.21% ATR1.63
Employees298 Current Ratio27.70 Sales Q/Q45.50% Oper. Margin59.40% RSI (14)50.77 Volatility3.08% 3.38%
OptionableYes Debt/Eq0.00 EPS Q/Q30.30% Profit Margin59.80% Rel Volume0.47 Prev Close46.20
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout0.00% Avg Volume664.23K Price45.42
Recom2.20 SMA200.13% SMA502.20% SMA200-32.80% Volume313,140 Change-1.69%
Sep-23-21Initiated Needham Buy $84
Jun-16-21Downgrade Citigroup Buy → Neutral $101 → $68
Apr-07-21Initiated Piper Sandler Overweight $100
Feb-26-21Downgrade Mizuho Buy → Neutral $81
Feb-25-21Reiterated H.C. Wainwright Neutral $74 → $86
Feb-02-21Resumed Raymond James Mkt Perform
Jan-22-21Downgrade BMO Capital Markets Outperform → Market Perform $95
Jan-04-21Upgrade Guggenheim Neutral → Buy
Jan-04-21Downgrade RBC Capital Mkts Outperform → Sector Perform $83 → $86
Dec-04-20Upgrade Mizuho Neutral → Buy $77 → $81
Dec-01-20Downgrade Raymond James Outperform → Mkt Perform
Nov-16-20Downgrade Morgan Stanley Overweight → Equal-Weight $87 → $85
Nov-06-20Reiterated H.C. Wainwright Neutral $76 → $81
Sep-11-20Upgrade Wedbush Neutral → Outperform
Aug-10-20Upgrade Raymond James Mkt Perform → Outperform $70
May-08-20Downgrade Wedbush Outperform → Neutral
Apr-08-20Downgrade Guggenheim Buy → Neutral
Mar-18-20Upgrade RBC Capital Mkts Sector Perform → Outperform $73 → $60
Mar-06-20Initiated Citigroup Buy $71
Feb-28-20Reiterated H.C. Wainwright Neutral $87 → $78
Sep-22-21 01:40PM  
Sep-20-21 02:57PM  
Sep-15-21 07:38AM  
Sep-02-21 06:30AM  
Aug-30-21 06:19AM  
Aug-25-21 11:16AM  
Aug-03-21 04:00PM  
Jul-27-21 03:03PM  
Jul-20-21 06:30AM  
Jul-13-21 09:07AM  
Jul-08-21 06:30AM  
Jun-29-21 06:04AM  
Jun-24-21 06:30AM  
Jun-21-21 10:19AM  
Jun-19-21 07:00AM  
Jun-17-21 08:13PM  
Jun-16-21 10:28AM  
Jun-15-21 04:17PM  
Jun-02-21 09:03AM  
May-27-21 08:40AM  
May-20-21 06:30AM  
May-13-21 08:48AM  
May-04-21 07:45AM  
Apr-28-21 06:30AM  
Apr-20-21 06:30AM  
Apr-14-21 12:54PM  
Apr-13-21 05:27PM  
Apr-12-21 04:40PM  
Apr-07-21 09:25AM  
Mar-25-21 06:10AM  
Mar-24-21 06:30AM  
Mar-21-21 06:11AM  
Mar-18-21 09:39AM  
Mar-17-21 06:30AM  
Mar-16-21 04:45PM  
Mar-04-21 04:28PM  
Feb-26-21 12:00AM  
Feb-25-21 07:09AM  
Feb-24-21 06:53AM  
Feb-11-21 05:00PM  
Feb-10-21 06:30AM  
Feb-07-21 01:44PM  
Jan-07-21 06:30AM  
Jan-04-21 10:04AM  
Dec-23-20 06:30AM  
Dec-22-20 09:39AM  
Dec-20-20 04:00AM  
Dec-19-20 07:46AM  
Dec-18-20 06:45AM  
Dec-16-20 06:30AM  
Dec-12-20 07:20AM  
Dec-09-20 07:54AM  
Dec-04-20 09:32AM  
Dec-03-20 04:30PM  
Dec-02-20 12:56PM  
Dec-01-20 11:55AM  
Nov-30-20 10:42AM  
Nov-29-20 09:32AM  
Nov-27-20 01:18PM  
Nov-18-20 12:04AM  
Nov-09-20 08:26AM  
Nov-05-20 09:31PM  
Nov-02-20 06:30AM  
Oct-22-20 06:30AM  
Oct-21-20 11:09AM  
Oct-19-20 05:00PM  
Oct-15-20 06:30AM  
Oct-01-20 07:00AM  
Sep-16-20 04:55PM  
Sep-15-20 09:56AM  
Sep-11-20 01:38PM  
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greene Barry EPresident and CEOAug 05Buy43.1523,6401,020,05432,440Aug 09 09:07 AM
JONAS JEFFREY MChief Innovation OfficerJun 16Option Exercise0.4512,0005,40075,237Jun 17 09:13 AM
IGUCHI KIMICFO & TreasurerJun 16Option Exercise1.362,0002,72044,533Jun 17 09:12 AM
FRATES JAMES MDirectorJun 16Buy55.101,81099,7351,810Jun 17 04:04 PM
Greene Barry EPresident and CEOJun 16Buy56.328,800495,6278,800Jun 17 09:14 AM
IGUCHI KIMICFO & TreasurerJun 15Option Exercise1.363,0004,08039,855Jun 17 09:12 AM
IGUCHI KIMICFO & TreasurerApr 13Option Exercise1.361,5002,04036,855Apr 14 04:36 PM
JONAS JEFFREY MChief Innovation OfficerJan 27Option Exercise0.451,80081056,330Jan 28 04:02 PM
IGUCHI KIMICFO & TreasurerJan 05Option Exercise1.361,7502,38035,355Jan 06 04:23 PM